AKT1 and B-cell non-Hodgkin lymphoma: In aggressive B-cell lymphoma, venetoclax resistance is mediated by the abnormal activation of the PI3K/AKT pathway due to the compromised expression of PTEN; the inhibitors targeting this pathway display synthetic lethality [56].